ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fulvestrant

Also written as “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, “fulvestrant” and “faslodex 500mg”.

Its studies are mostly in Breast Neoplasms · Neoplasms · Carcinoma, Intraductal, Noninfiltrating · Puberty, Precocious · Endometrial Neoplasms, led by 5 companies.

Drug pageFulvestrant: every studyMany companies study it; this page follows only the 25 they lead. All 122 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 4, 201525 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only211 open or runningphase 4since May 4, 2015Jul 21, 2003none ahead
Atossa Therapeuticsits history only10 open or runningphase 2since Aug 28, 2015Aug 28, 2015none ahead
Criterium11 open or runningphase 2since Sep 3, 2020Sep 3, 2020Dec 31, 2027phase 2 · NCT04567420
Eagle Pharmaceuticalsits history only10 open or runningphase 1since Oct 24, 2017Oct 24, 2017none ahead
Fresenius Kabiits history only10 open or runningphase 1since May 30, 2016May 30, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Criterium only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2020First study: phase 2 study in Breast NeoplasmsFirst studyNCT04567420 · 70 enrolled · United States

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT04567420

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha antagonist; Estrogen receptor degrader”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

The one study Criterium leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04567420Breast Neoplasms · United States2Active, not recruitingDec 31, 202770

How it is read

Names in the registry

  • “Fulvestrant”, 26 entries
  • “PF-07104091 + PF-07220060 + fulvestrant dose expansion”, 2 entries
  • “fulvestrant”, 2 entries
  • “faslodex 500mg”, 1 entry
  • “Fulvestrant injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.